These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27657882)

  • 1. Disease Status and Pubertal Stage Predict Improved Growth in Antitumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease.
    Cameron FL; Altowati MA; Rogers P; McGrogan P; Anderson N; Bisset WM; Ahmed SF; Wilson DC; Russell RK
    J Pediatr Gastroenterol Nutr; 2017 Jan; 64(1):47-55. PubMed ID: 27657882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNF therapy for paediatric IBD: the Scottish national experience.
    Cameron FL; Wilson ML; Basheer N; Jamison A; McGrogan P; Bisset WM; Gillett PM; Russell RK; Wilson DC
    Arch Dis Child; 2015 Apr; 100(4):399-405. PubMed ID: 25678594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab vs Infliximab in Luminal Pediatric Crohn's Disease: Comparable Outcomes in a Prospective Multicenter Cohort Study.
    deBruyn JC; Huynh HQ; Griffiths AM; Jacobson K; Mack D; Deslandres C; El-Matary W; Otley AR; Church PC; Lawrence S; Wine E; Sherlock M; Critch J; Benchimol EI; Jantchou P; Rashid M; Carroll MW; Bax K; Ricciuto A; Carman N; Walters TD;
    Am J Gastroenterol; 2024 Mar; 119(3):565-575. PubMed ID: 37787642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort.
    Chanchlani N; Mortier K; Williams LJ; Muhammed R; Auth MKH; Cosgrove M; Fagbemi A; Fell J; Chong S; Zamvar V; Hyer W; Bisset WM; Morris MA; Rodrigues A; Mitton SG; Bunn S; Beattie RM; Willmott A; Wilson DC; Russell RK
    J Pediatr Gastroenterol Nutr; 2018 Oct; 67(4):513-519. PubMed ID: 29697550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal healing in pediatric Crohn's disease after anti-TNF therapy: a long-term experience at a single center.
    Nobile S; Gionchetti P; Rizzello F; Calabrese C; Campieri M
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):458-65. PubMed ID: 24445727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
    Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
    Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Long-term follow-up of inflammatory bowel disease patients receiving anti-tumor necrosis factor-alpha therapy].
    Bacsur P; Skribanek S; Milassin Á; Farkas K; Bor R; Fábián A; Rutka M; Bálint A; Szántó KJ; Tóth T; Nagy F; Szepes Z; Boda K; Molnár T
    Orv Hetil; 2020 Nov; 161(47):1989-1994. PubMed ID: 33226355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
    Lecoutour A; Dupont C; Caldari D; Dumant C; Vanrenterghem A; Ruiz M; Duclaux-Loras R; Berthet S; Dimitrov G; Lacroix D; Duvant P; Roman C; Wagner AC; Bourmaud A; Viala J; Ruemmele FM; Pigneur B;
    J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1116-1125. PubMed ID: 38314896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
    Macaluso FS; Fries W; Privitera AC; Cappello M; Siringo S; Inserra G; Magnano A; Di Mitri R; Mocciaro F; Belluardo N; Scarpulla G; Magrì G; Trovatello A; Carroccio A; Genova S; Bertolami C; Vassallo R; Romano C; Citrano M; Accomando S; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Porcari S; Ferracane C; Cottone M; Orlando A;
    J Crohns Colitis; 2019 Feb; 13(2):209-217. PubMed ID: 30295785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elective switching from infliximab to adalimumab in stable Crohn's disease.
    Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
    Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.
    Varma P; Paul E; Huang C; Headon B; Sparrow MP
    Intern Med J; 2016 Jul; 46(7):798-804. PubMed ID: 26865349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice.
    Patil SA; Rustgi A; Langenberg P; Cross RK
    Dig Dis Sci; 2013 Jan; 58(1):209-15. PubMed ID: 23014844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
    Kim JY; Lee Y; Choe BH; Kang B
    Gut Liver; 2021 Jul; 15(4):588-598. PubMed ID: 33024062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for pediatric Crohn's disease].
    Navas-López VM; Pujol Muncunill G; Llerena E; Navalón Rubio M; Gil-Ortega D; Varea-Calderón V; Sierra Salinas C; Martin-de-Carpi J
    An Pediatr (Engl Ed); 2018 Feb; 88(2):89-99. PubMed ID: 28434894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's Disease.
    Ebach DR; Jester TW; Galanko JA; Firestine AM; Ammoury R; Cabrera J; Bass J; Minar P; Olano K; Margolis P; Sandberg K; Linnville TM; Kaplan J; Pitch L; Steiner SJ; Bass D; Moses J; Adler J; Gulati AS; Wali P; Pashankar D; Ivanova A; Herfarth H; Wohl DA; Benkov KJ; Strople J; Sullivan J; Tung J; Molle-Rios Z; Saeed SA; Bousvaros A; Kappelman MD
    Am J Gastroenterol; 2024 Jun; 119(6):1110-1116. PubMed ID: 38445644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with anti-TNF-α therapy for orofacial granulomatosis.
    Elliott T; Campbell H; Escudier M; Poate T; Nunes C; Lomer M; Mentzer A; Patel P; Shirlaw P; Brostoff J; Challacombe S; Sanderson J
    J Oral Pathol Med; 2011 Jan; 40(1):14-9. PubMed ID: 21249727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of anti-TNF-α treatment with adalimumab on growth in children with Crohn's disease (CD).
    Malik S; Ahmed SF; Wilson ML; Shah N; Loganathan S; Naik S; Bourke B; Thomas A; Akobeng AK; Fagbemi A; Wilson DC; Russell RK
    J Crohns Colitis; 2012 Apr; 6(3):337-44. PubMed ID: 22405171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.
    Gisbert JP; Marín AC; McNicholl AG; Chaparro M
    Aliment Pharmacol Ther; 2015 Apr; 41(7):613-23. PubMed ID: 25652884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
    Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
    J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.